Leman Biotech’s Post

Pharma pipelines can vary significantly by modality across different geographies. Building on a strong legacy of iPSC-based research, Japanese pharma has a larger proportion of cell therapies in their pipelines compared to other global players. Moreover, small molecules still represent the most common modality in Japan compared to a clear preference for monoclonal antibodies within Global pharma. In a related development this week, BlueRock Therapeutics has received clearance for its induced pluripotent stem cell (iPSC)-derived cell therapy IND application for the treatment of primary photoreceptor diseases. This is the first drug candidate spawned through the collaboration between FUJIFILM Cellular Dynamics, Opsis Tx and BlueRock Tx to discover and develop off-the-shelf iPSC-derived cell therapies for ocular diseases. https://lnkd.in/gty39Yfg

Learn about the pivotal role of materials science in cancer care! Discover how innovative polymer-based drug delivery systems improve precision targeting and treatment specificity, reducing side effects. Stay informed with this insightful AZoMaterials article: https://lnkd.in/ewMr3kkM #MaterialsScience #CancerCare #Innovation

In the wake of the US FDA granting accelerated approval to Adaptimmune's #Tecelra, the cell therapy landscape is abuzz with anticipation. Tecelra, the second autologous cell therapy approved for solid tumors, stands out as a first-in-class therapy due to its innovative manufacturing process. Unlike its predecessor, Tecelra's approach involves ex vivo engineering, setting it apart in the realm of cell therapies. The approval of Tecelra marks a significant milestone, sparking renewed enthusiasm among oncologists and drugmakers for the future of cell therapy. #CellTherapy #FDAApproval #Innovation #patientderived #autologus #celltherapy #solidtumor #exvivorngineering #advancedtherapies #regenerativemedicine #acceleratedapproval #commercialization #biotech #biotechnology #lifescience #lifesciences #innovativemanufacturing #manufacturing #commercialpathway

Mitochondrial respiration is critical for the function and survival of CAR-T cells in adoptive cell therapies. Recent research highlights the role of methylation-controlled J protein (MCJ) as a negative regulator of mitochondrial complex I in CD8 cells, showing that silencing MCJ enhances mitochondrial metabolism and improves the efficacy of CAR-T cells against tumors.  - I am currently working on integrating OCR monitoring into the CAR-T cell manufacturing process. My goal is to explore the potential of selecting CAR-T cells with high OCR, enhancing their therapeutic effectiveness. I am seeking collaborators for this research proposal. If you are interested, please feel free to reach out to me. - ref. Deleting the mitochondrial respiration negative regulator MCJ enhances the efficacy of CD8+ T cell adoptive therapies in pre-clinical studies (https://lnkd.in/gpfWkQhi) #CellTherapy #Immunotherapy #CancerResearch

I am happy to share our research publication, " Immobilized doxorubicin and ribociclib carbamate linkers encaged in surface modified cubosomes spatially target tumor reductive environment to enhance antitumor efficacy." This article has been published in #BiomaterialsAdvances (Impact Factor 7.9; Scopus Q1). Article link: https://lnkd.in/gdkHHyVk #PublicationAlert #PharmaceuticalSciences #PharmaceuticalResearch #BiomaterialsAdvances #Elsevier

Congratulations on NX-2127! Hope it would be launched in the near future. By design, #NX-2127 mediates the degradation of transcription factors IKZF1 and IKZF3 through molecular glue interactions with the cereblon #E3 ubiquitin #ligase complex. NX-2127 degrades common #BTK resistance mutants, including BTKC481S. NX-2127 is orally bioavailable, exhibits in vivo degradation across species, and demonstrates efficacy in #preclinical oncology models. NX-2127 has advanced into first-in-human #clinical trials and achieves deep and sustained degradation of BTK following daily oral dosing at 100 mg. #Protac #nurix #preclinical #oncology #Degradation #TPD #PROTACs #DrugDiscovery #CRO #CMC https://lnkd.in/gZgPv7Qe

The digital soft agar colony formation (D-SAC) assay is a highly sensitive test for detecting malignant transformed cells as impurities in human cell therapy products (hCTPs). MEASURE Consortium, which consisted of NIHS and FIRM-CoNCEPT, performed a multisite validation of the D-SAC assay to confirm its performance and established optimal assay conditions for testing tumorigenic impurities in hCTP with high sensitivity and arbitrary false negative rates. https://lnkd.in/g8pq-SUJ

📣 NEWS! Today, Feb 29th at the 7th CAR-TCR Summit Series Europe, BioCentriq and Terumo Blood and Cell Technologies shared the first data resulting from its chimeric antigen receptor (CAR)-T cell therapy manufacturing collaboration. The data demonstrates for the first time, the ability to rapidly produce CAR-T cells using protocols developed by Terumo BCT for its Quantum Flex and Finia® Fill and Finish System platforms, even when starting material is scarce. BioCentriq generated the data on the two platforms in tandem with our LEAP™ Advanced Therapy Platform. "This collaboration takes aim at the manufacturing bottlenecks that have adversely impacted patient access to CAR-T's and other advanced therapies," said David Smith, Ph.D., Vice President of Development at BioCentriq. "It demonstrates how BioCentriq is leveraging Terumo BCT's platforms to shorten manufacturing timelines and accelerate the development of new therapies." BioCentriq performed several runs through the manufacturing process after receiving protocols from Terumo BCT to optimize cell expansion in the Quantum Flex and fill/finish in the Finia. To evaluate the platform's capabilities, a range of starting cell numbers were assessed from 1 million through 15 million cells. These expanded to between 200 million to 2.6 billion in 7 days. As these starting cells often come from patients who may have difficulty producing enough when ill or in treatment, we found the three platforms working together can support sufficient expansion with starting material as low as 1 million CAR-T cells. https://lnkd.in/eXnQdDtR #CARTCR24 #advancedtherapies #cartcelltherapy #CART #celltherapy #cancer #biocentriq #terumo #manufacturing #collaboration #HOPE

Exceptional Allogeneic CAR-T News from Poseida Therapeutics, Inc.! Congratulations Kristin Yarema, Ph.D. and team! ...Poseida Therapeutics says the lead allogeneic chimeric antigen receptor T-cell (CAR-T) candidate it is co-developing with Roche through an up-to-$6.2 billion-plus collaboration will advance to Phase Ib after generating positive interim clinical data in the Phase I portion of an early-stage trial in patients with relapsed/refractory multiple myeloma (RRMM). That lead candidate, P-BCMA-ALLO1, is an off-the-shelf, B-cell maturation antigen (BCMA)-targeted allogeneic, T stem cell memory (TSCM)-rich CAR-T therapy. P-BCMA-ALLO1 showed a 91% overall response rate (ORR) and safety results the companies termed “compelling” among 23 heavily pretreated patients in the optimized lymphodepletion arm, called “Arm C,” of the trial’s Phase I portion.... #celltherapy #clinicaltrials #data #advancedtherapies #regenerativemedicine #CarTtherapies #multiplemyeloma #oncology #cancer #lifescience #lifesciences #biotech #biotechnology #cancertreatments

Programming B cells to treat Mucopolysaccharidosis Type I - Immusoft to Announce Positive Phase 1 Data for First Engineered B Cell Therapy in a Clinical Trial @immusoft #celltherapy #genetherapy